In this video, Beth Sandy, MSN, CRNP, FAPO, discusses ivonescimab, a bispecific antibody targeting PD-1 and VEGF that produced a tolerable safety profile and clinically significant improvement in efficacy compared with pembrolizumab.
Beth Sandy, MSN, CRNP, FAPO Thoracic Oncology Nurse Practitioner Abramson Cancer Center, University of Pennsylvania Philadelphia, PA
Sponsored by
In the final video of this Rapid Reactions series, Beth Sandy, MSN, CRNP, FAPO, discusses data that continue to favor first-line amivantamab plus lazertinib over osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer after a median of 31 months of follow-up.
In this video, Beth Sandy, MSN, CRNP, FAPO, discusses data showing that zongertinib demonstrated manageable safety and promising efficacy in patients with HER2 aberration-positive solid tumors, including those with baseline brain metastases.
Zongertinib, a HER2 TKI, demonstrated clinically meaningful activity and tolerability in patients with NSCLC with and without brain metastases harboring a HER2 mutation.
Keep up to date with the latest news from us via social networks:
To sign up for our print publication or e-newsletter, please enter your contact information below.
